Amgen drug combined with immunotherapy extends survival in lung cancer trial Reuters
Amgen drug combined with immunotherapy extends survival in lung cancer trial - Reuters
In short
Amgen's drug, combined with immunotherapy, extended the survival of patients with advanced lung cancer in a clinical trial, significantly improving survival rates by an average of 7.5 months compared to standard treatment. This study, published in the New England Journal of Medicine, is a groundbreaking development in lung cancer treatment and has the potential to revolutionize the way this disease is approached.
Key points
- Amgen's drug, combined with immunotherapy, extended the survival of patients with advance…: Amgen's drug, combined with immunotherapy, extended the survival of patients with advanced lung cancer in a clinical trial, significantly improving survival rates by an average of 7.5 months compared to standard treatment.
- The study involved 150 patients and was conducted at multiple centers across the United S…: The study involved 150 patients and was conducted at multiple centers across the United States and Europe.
- The results were published in the New England Journal of Medicine, making it a significan…: The results were published in the New England Journal of Medicine, making it a significant breakthrough in lung cancer treatment.